Unknown

Dataset Information

0

Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain.


ABSTRACT: The treatment of neuropathic pain is one of the urgent unmet medical needs and T-type calcium channels are promising therapeutic targets for neuropathic pain. Several potent T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain animal models and are being investigated in clinical trials. Herein we report development of novel pyrrolidine-based T-type calcium channel inhibitors by pharmacophore mapping and structural hybridisation followed by evaluation of their Cav3.1 and Cav3.2 channel inhibitory activities. Among potent inhibitors against both Cav3.1 and Cav3.2 channels, a promising compound 20n based on in vitro ADME properties displayed satisfactory plasma and brain exposure in rats according to in vivo pharmacokinetic studies. We further demonstrated that 20n effectively improved the symptoms of neuropathic pain in both SNL and STZ neuropathic pain animal models, suggesting modulation of T-type calcium channels can be a promising therapeutic strategy for the treatment of neuropathic pain.

SUBMITTER: Yang HK 

PROVIDER: S-EPMC6151954 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain.

Yang Hak Kyun HK   Son Woo Seung WS   Lim Keon Seung KS   Kim Gun Hee GH   Lim Eun Jeong EJ   Gadhe Changdev G CG   Lee Jae Yeol JY   Jeong Kyu-Sung KS   Lim Sang Min SM   Pae Ae Nim AN  

Journal of enzyme inhibition and medicinal chemistry 20181201 1


The treatment of neuropathic pain is one of the urgent unmet medical needs and T-type calcium channels are promising therapeutic targets for neuropathic pain. Several potent T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain animal models and are being investigated in clinical trials. Herein we report development of novel pyrrolidine-based T-type calcium channel inhibitors by pharmacophore mapping and structural hybridisation followed by evaluation of their Ca<sub>v<  ...[more]

Similar Datasets

| S-EPMC3326631 | biostudies-literature
| S-EPMC4056936 | biostudies-literature
| S-EPMC6429214 | biostudies-literature
| S-EPMC9714965 | biostudies-literature
| S-EPMC8757610 | biostudies-literature
| S-EPMC5482218 | biostudies-literature
| S-EPMC3945363 | biostudies-literature
| S-EPMC10303112 | biostudies-literature
| S-EPMC6399680 | biostudies-literature
| S-EPMC4111572 | biostudies-literature